37 citations
,
January 2010 in “International Journal of Trichology” In this 1-year study of patients with alopecia areata universalis, researchers found that 0.03% topical bimatoprost led to an acceptable cosmetic response in 43.24% of participants.
May 2025 in “Dermatology Online Journal” This report describes a rare case of eyelash overgrowth and eyelid irritation in a woman treated with erlotinib for lung adenocarcinoma, highlighting a potential side effect of the drug.
57 citations
,
August 2023 in “American Journal of Clinical Dermatology” JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.
11 citations
,
January 2012 in “PubMed” This case report suggests that topical bimatoprost may promote eyebrow hair growth, as observed in a patient with eyebrow hypotrichosis, but lacks broader published scientific evidence.
21 citations
,
January 2007 in “Journal of the European Academy of Dermatology and Venereology” This study reports that periocular pigmentation may occur with the use of travoprost for treating alopecia areata of the eyelashes.
January 2015 in “Annals of dermatology/Annals of Dermatology” This report describes a case where travoprost treatment for open-angle glaucoma was associated with periocular hypertrichosis, hyperpigmentation, and eyelash growth, which gradually improved after discontinuation.
23 citations
,
April 2004 in “American Journal of Ophthalmology” This case report found that topical bimatoprost usage in a female Hispanic patient with open-angle glaucoma was associated with hypertrichosis and increased pigmentation of vellus hairs on the malar region.
15 citations
,
March 2004 in “American Journal of Ophthalmology” This case report found that topical bimatoprost in a female Hispanic patient with glaucoma led to increased hair growth and pigmentation in the malar region, which resolved after discontinuing use and epilation.
2 citations
,
February 2016 in “British Journal of Dermatology” This study found that topical bimatoprost significantly improved eyelash growth in individuals with idiopathic and chemotherapy-induced eyelash hypotrichosis compared to a vehicle treatment.
9 citations
,
January 2014 in “Dermatology online journal” This pilot study evaluated bimatoprost ophthalmic solution 0.03% for eyebrow hair regrowth in ten female patients, but reports no new clinical results.
April 2010 in “PubMed Central” This abstract discusses the FDA approval of Latisse (bimatoprost) for increasing eyelash growth in patients with eyelash hypotrichosis and highlights its efficacy while noting unresolved effectiveness in certain conditions and potential side effects.
69 citations
,
April 2010 in “Clinical ophthalmology” This article reviews the use of bimatoprost for eyelash hypotrichosis and reports its effectiveness in promoting eyelash growth but highlights uncertain efficacy in cases of eyelash alopecia areata.
39 citations
,
March 2009 in “Dermatology Online Journal” This review observes that trichomegaly, a newly described side effect of EGFR inhibitors causing excessive eyelash and scalp hair growth, persists in some patients whose tumors respond positively to the therapy.
38 citations
,
October 2014 in “British journal of dermatology/British journal of dermatology, Supplement” The study found that daily use of bimatoprost ophthalmic solution 0.03% for one year was effective in improving eyelash growth and patient satisfaction in both idiopathic and chemotherapy-induced hypotrichosis, with no serious drug-related adverse events reported.
7 citations
,
May 2018 in “Curēus” In this case report, a 60-year-old woman with eyebrow hypotrichosis experienced significant and lasting eyebrow growth after daily use of bimatoprost 0.03% solution, highlighting its potential as an effective treatment for eyebrow hair restoration.
9 citations
,
July 2017 in “Journal of medical case reports” This study reports the first case of eyelash elongation and thickening in a patient with hypereosinophilic syndrome taking the Janus kinase inhibitor ruxolitinib.
162 citations
,
August 2002 in “Survey of Ophthalmology” This study found that latanoprost induces significant growth and pigmentation of lashes and ancillary hairs, with effects mirroring both brief and chronic treatments observed in patients and animal models.
16 citations
,
March 2016 in “Clinical ophthalmology” In this study, bimatoprost 0.03% was effective and well-tolerated for improving eyelash hypotrichosis in healthy adolescents, but not for those with the condition due to chemotherapy or alopecia areata.
April 2016 in “British Journal of Dermatology” Eyelashes are important for looks and eye protection, and more people are treating sparse eyelashes; more research is needed to understand eyelash biology and improve treatments.
35 citations
,
March 2010 in “British journal of dermatology/British journal of dermatology, Supplement” This study demonstrates that mouse eyelashes can effectively model human eyelash growth to analyze morphology, development, and the effects of growth-stimulatory agents like bimatoprost.
34 citations
,
February 2018 in “Drug Design Development and Therapy” This source reports that bimatoprost, a medication approved for eyelash growth, has shown efficacy in treating eyebrow hypotrichosis, suggesting it as a noninvasive, effective, and well-tolerated option for enhancing eyebrow hair.
29 citations
,
May 2010 in “Ophthalmology” Bimatoprost gel makes eyelashes grow longer, but may cause side effects and should be monitored by an eye doctor.
12 citations
,
November 2006 in “Journal of thoracic oncology” This case report describes a patient with non-small cell lung cancer who experienced trichomegaly (excessive eyelash growth) as a side effect of erlotinib treatment without developing typical skin rash.
January 2010 in “Yearbook of Dermatology and Dermatologic Surgery” Topical latanoprost and bimatoprost ophthalmic solutions don't help eyelash growth in patients with alopecia areata.
69 citations
,
April 2010 in “Dermatologic Surgery” This review discusses the safety and efficacy of bimatoprost ophthalmic solution 0.03% for enhancing eyelash growth by influencing the eyelash hair cycle and follicles, and it reports no new results.
38 citations
,
March 2017 in “Expert Opinion on Investigational Drugs” This review examines the potential of bimatoprost for treating various types of eyelash and eyebrow hypotrichosis, discussing its pharmacological properties but providing no new clinical results.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.
5 citations
,
July 2010 in “Archives of Internal Medicine” This study observed that topical prostaglandin treatments may protect against hair follicle injury during chemotherapy, as indicated by preserved eyelashes in patients using these treatments.
October 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in improving treatment outcomes and staying updated on various health conditions.